Panacea Biotec Limited

Company Profile

Panacea Biotec Limited had its IPO on under the ticker symbol 531349.

The company operates in the Healthcare sector and Biotechnology industry. Panacea Biotec Limited has a staff strength of 0 employees.

Stock update

Shares of Panacea Biotec Limited opened at ₹136.4 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹129.1 - ₹137.6, and closed at ₹130.1.

This is a -3.67% slip from the previous day's closing price.

A total volume of 51,660 shares were traded at the close of the day’s session.

In the last one week, shares of Panacea Biotec Limited have slipped by -3.45%.

Panacea Biotec Limited's Key Ratios

Panacea Biotec Limited has a market cap of ₹11.09 billion, indicating a price to book ratio of 3.8603 and a price to sales ratio of 2.1018.

In the last 12-months Panacea Biotec Limited’s revenue was ₹6.08 billion with a gross profit of ₹3.87 billion and an EBITDA of ₹998.60 million. The EBITDA ratio measures Panacea Biotec Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Panacea Biotec Limited’s operating margin was 9.12% while its return on assets stood at 2.69% with a return of equity of -192.75%.

In Q3, Panacea Biotec Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Panacea Biotec Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

17.4577

PEG

Its diluted EPS in the last 12-months stands at ₹-34.637 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Panacea Biotec Limited’s profitability.

Panacea Biotec Limited stock is trading at a EV to sales ratio of 3.085 and a EV to EBITDA ratio of 6.4905. Its price to sales ratio in the trailing 12-months stood at 2.1018.

Panacea Biotec Limited stock pays annual dividends of ₹ per share, indicating a yield of 1.82% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹12.71 billion

Total Liabilities

₹3.32 billion

Operating Cash Flow

₹4.30 billion

Capital Expenditure

₹409.50 million

Dividend Payout Ratio

0%

Panacea Biotec Limited ended 2024 with ₹12.71 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹12.71 billion while shareholder equity stood at ₹8.44 billion.

Panacea Biotec Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.32 billion in other current liabilities, 61300000.00 in common stock, ₹8.37 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹398.50 million and cash and short-term investments were ₹2.42 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹201.60 million.

Panacea Biotec Limited’s total current assets stands at ₹5.68 billion while long-term investments were ₹0 and short-term investments were ₹2.02 billion. Its net receivables were ₹600.90 million compared to accounts payable of ₹0 and inventory worth ₹2.02 billion.

In 2024, Panacea Biotec Limited's operating cash flow was ₹4.30 billion while its capital expenditure stood at ₹409.50 million.

Comparatively, Panacea Biotec Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹130.1

52-Week High

₹165

52-Week Low

₹107.15

Analyst Target Price

₹

Panacea Biotec Limited stock is currently trading at ₹130.1 per share. It touched a 52-week high of ₹165 and a 52-week low of ₹165. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹131.34 and 200-day moving average was ₹127.79 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 8696.4% of the company’s stock are held by insiders while 127.8% are held by institutions.